Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of pat...Show More
peer of
investor of
competitor of
Metrics
marketSTOCKS
msh_idCOM:EXELIXIS
localeus
websitehttps://www.exelixis.com
ipo_date2000-04-17
primary_stock_msh_idNASDAQ:EXEL
source_ref5080de05-1057-4780-b323-5678b413b5cb
products_or_servicesResearch and development of cancer therapies, including small molecule programs and biotherapeutics.